-
Views
-
Cite
Cite
Jaya Punati, James Markowitz, Trudy Lerer, Jeffrey Hyams, Subra Kugathasan, Anne Griffiths, Anthony Otley, Joel Rosh, Marian Pfefferkorn, David Mack, Jonathan Evans, Athos Bousvaros, Susan M. Moyer, Robert Wyllie, Maria Oliva-Hemker, Adam Mezoff, Neal LeLeiko, David Keljo, Wallace Crandall, Effect of early immunomodulator use in moderate to severe pediatric Crohn disease, Inflammatory Bowel Diseases, Volume 14, Issue 7, 1 July 2008, Pages 949–954, https://doi.org/10.1002/ibd.20412
Close - Share Icon Share
The immunomodulators (IMs) 6-mercaptopurine and azathioprine decrease corticosteroid dependence and maintain remission in Crohn's disease (CD). We describe IM use in newly diagnosed pediatric CD, comparing outcomes of “early” versus “late” initiation of therapy.
Data were obtained from pediatric CD patients enrolled in a prospective, multicenter observational study. Moderate/severe disease patients treated with IM were compared for outcomes of remission, corticosteroid use, infliximab therapy, hospitalizations, and CD-related surgery based on timing of initiation of IM therapy.
In all, 247 children met the criteria (60% male, mean age 11.9 years); 199 were treated with IM within 1 year of diagnosis; 150 between 0–3 months (early), 49 between 3–12 months (late). Both groups showed a decrease in corticosteroid use by 12 months, at which time proportionately fewer early group patients had received corticosteroids in the preceding quarter (22%) than late groups patients (41%)(P = 0.013). The number of hospitalizations per patient was also noted to be significantly lower in the early group over the 2-year follow-up (P = 0.03). No difference was noted in the rates of remission, infliximab use over time, or surgery.
80% of children with newly diagnosed moderate to severe CD are treated with IM within 1 year. Early IM use is associated with reduced corticosteroid exposure and possibly fewer hospitalizations per patient.
